|
|||||
![]() |
|
Tobacco company Altria (NYSE:MO) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $5.29 billion. Its non-GAAP profit of $1.44 per share was 4% above analysts’ consensus estimates.
Is now the time to buy MO? Find out in our full research report (it’s free).
Altria’s second quarter results were well received by the market, as the company surpassed Wall Street’s revenue and profit expectations despite flat sales year over year. Management attributed the performance to robust growth in the oral tobacco segment, particularly from the on! nicotine pouch brand, which led to substantial profit gains within the segment. CEO William Gifford emphasized the success of targeted marketing efforts and increased brand awareness for on!, noting that “on!’s improving financial performance drove the majority of the oral segment’s substantial profit growth for the quarter.” The company also cited disciplined price management and targeted efforts in the discount cigarette segment as important contributors.
Looking ahead, Altria’s guidance is shaped by ongoing investments in smoke-free products and heightened attention to U.S. regulatory enforcement against illicit e-vapor imports. Management expects continued challenges from inflation and evolving consumer behavior, but remains focused on expanding product options and maintaining profitability. CFO Salvatore Mancuso highlighted that “guidance does contemplate our continued support of our vision and the development of product pipeline within the smoke-free innovative tobacco categories.” Management is also closely monitoring macroeconomic pressures and potential shifts in consumer spending, especially among low-income tobacco users.
Management credited strong oral tobacco growth and disciplined pricing as primary contributors to Q2 performance, while also noting regulatory and supply chain factors shaping the outlook.
Management expects future performance to hinge on smoke-free product investments, regulatory enforcement trends, and evolving consumer purchasing behavior.
In the coming quarters, the StockStory team will monitor (1) the pace of regulatory enforcement and its effect on illicit e-vapor market share, (2) the adoption and profitability of new and existing smoke-free products like on! and the planned NJOY relaunch, and (3) consumer behavior in response to inflation and targeted pricing strategies. Progress in FDA product authorizations and the company’s response to evolving regulatory policies will also be key factors.
Altria currently trades at $65.70, up from $59.39 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Sep-11 | |
Sep-11 | |
Sep-10 | |
Sep-08 | |
Sep-08 | |
Sep-05 | |
Sep-04 | |
Sep-03 | |
Sep-03 | |
Sep-03 | |
Sep-02 | |
Sep-02 | |
Sep-02 | |
Aug-31 | |
Aug-30 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite